These dividend stocks all pay yields of around 6% and higher.

5 Stocks to Buy for a Harris Presidency

02:12pm, Monday, 21'st Oct 2024
The race for the White House is heating up and these five stocks are set to benefit if Kamala Harris claims victory.
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In the closing of the recent trading day, Organon (OGN) stood at $18.10, denoting a +0.56% change from the preceding trading day.
Organon (OGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, will release its third quarter 2024 financial results on October 31, 2024, prior to
Organon (OGN) closed at $18.10 in the latest trading session, marking a -0.11% move from the prior day.
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) concluded the recent trading session at $18.58, signifying a -1.33% move from its prior day's close.

Final Trades: Organon, Howmet and the PSQ

01:35pm, Wednesday, 02'nd Oct 2024
The Investment Committee give you their top stocks to watch for the second half.

Why Organon (OGN) Outpaced the Stock Market Today

07:05pm, Thursday, 26'th Sep 2024
Organon (OGN) reachead $19.17 at the closing of the latest trading day, reflecting a +0.74% change compared to its last close.
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.

Roivant Flips a Skin Drug to Organon

10:59am, Wednesday, 18'th Sep 2024
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Healthcare company Organon said on Wednesday it has agreed to acquire Dermavant, a Roivant company, for up to $1.2 billion.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE